Provided by Tiger Fintech (Singapore) Pte. Ltd.

Shuttle Pharmaceuticals Inc

0.4256
+0.01062.55%
Volume:189.56K
Turnover:83.23K
Market Cap:2.66M
PE:-0.10
High:0.4900
Open:0.4000
Low:0.4000
Close:0.4150
Loading ...

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

GlobeNewswire
·
26 Nov 2024

Shuttle Pharmaceuticals Q3 EPS $(1.59) Down From $(0.91) YoY

Benzinga
·
14 Nov 2024

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

THOMSON REUTERS
·
14 Nov 2024

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

GlobeNewswire
·
14 Nov 2024

Shuttle Pharmaceuticals Prices $4.5 Million Public Offering

MT Newswires Live
·
30 Oct 2024

Shuttle Pharmaceuticals dips 6%, prices $4.5M share offering

seekingalpha
·
30 Oct 2024

BRIEF-Shuttle Pharmaceuticals Holdings Announces Pricing Of $4.5 Mln Public Offering

Reuters
·
30 Oct 2024

Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share

TIPRANKS
·
30 Oct 2024

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
30 Oct 2024

Shuttle Pharmaceuticals Holdings Inc - Prices Public Offering of up to 2.9 Mln Shares of Common Stock and Warrants at$1.525 per Share

THOMSON REUTERS
·
30 Oct 2024

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
30 Oct 2024

Shuttle Pharma Pays off Senior Secured Convertible Note

THOMSON REUTERS
·
30 Oct 2024

Shuttle Pharma Pays Off Senior Secured Convertible Note

GlobeNewswire
·
30 Oct 2024

US Stocks Mixed; McDonald's Posts Upbeat Earnings

Benzinga
·
29 Oct 2024

Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine

TIPRANKS
·
29 Oct 2024

Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma

THOMSON REUTERS
·
29 Oct 2024